Capricor Therapeutics (CAPR) Return on Capital Employed (2011 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Return on Capital Employed of 39.0% for Q1 2026, up 197.0% year-over-year from 13.13% in Q1 2025, and up 25.93% quarter-over-quarter from 52.66% in Q4 2025.
Capricor Therapeutics (CAPR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Capricor Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 39.0% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 197.0% year-over-year to 39.0%; the TTM figure through Mar 2026 stood at 39.0% (up 197.0% YoY), while the FY2025 annual figure was 47.56%, down 208.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 39.0%, up from 52.66% in the prior quarter.
- The five-year high for Return on Capital Employed was 38.45% in Q4 2024, with the low at 356.58% in Q3 2023.
- The 5-year median for Return on Capital Employed is 85.1% (2025), against an average of 109.16%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed plunged 27119 bps in 2023, then surged 27650 bps in 2024.
- Capricor Therapeutics' Return on Capital Employed stood at 104.48% in 2022, then sank by 38 bps to 144.41% in 2023, then surged by 73 bps to 38.45% in 2024, then sank by 37 bps to 52.66% in 2025, then gained by 26 bps to 39.0% in 2026.
- Business Quant data shows CAPR's Return on Capital Employed at 39.0% in Q1 2026, 52.66% in Q4 2025, and 85.1% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | -39.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.00% |
| Dec 31, 2025 | -52.66% |
| Sep 30, 2025 | -85.10% |
| Jun 30, 2025 | -63.68% |
| Mar 31, 2025 | -40.98% |
| Dec 31, 2024 | -38.45% |
| Sep 30, 2024 | -80.08% |
| Jun 30, 2024 | -139.51% |
| Mar 31, 2024 | -94.42% |
| Dec 31, 2023 | -144.41% |
| Sep 30, 2023 | -356.58% |
| Jun 30, 2023 | -206.15% |
| Mar 31, 2023 | -202.40% |
| Dec 31, 2022 | -104.48% |
| Sep 30, 2022 | -85.39% |
| Jun 30, 2022 | -61.62% |
| Mar 31, 2022 | -60.84% |
| Dec 31, 2021 | -54.98% |
| Sep 30, 2021 | -48.64% |
| Jun 30, 2021 | -47.55% |